VEGFA and nonpapillary renal cell carcinoma: The standard therapy for ccRCC patients includes tyrosine kinase inhibitors targeting the VEGF signaling pathway, such as sunitinib and pazopanib, and mTOR kinase inhibitors, such as, everolimus and temsiromus [5, 6].